Crestor Advisory Meeting Weighs Value Of C-Reactive Protein Risk Marker
• By The Pink Sheet
In deciding whether to approve AstraZeneca's Crestor (rosuvastatin) for wider use, FDA will need to say what role high sensitive C-reactive protein levels will play in determining who should take the statin as a preventive measure. Until then, the size of Crestor's market opportunity for the pending claim remains somewhat unclear
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
HHS Secretary Kennedy's new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.